KCPG
AEGR

Kavar Capital Partners Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Kavar Capital Partners Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3
Closed – – 593
2013
Q4 		$0 Buy
+3
New +$229 ﹤0.01% 528

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Kavar Capital Partners Group's AEGR Position: Q1 2014 in Review

Kavar Capital Partners Group sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 3 shares.

Kavar Capital Partners Group first reported a position in AEGR in Q4 2013 and held it in 1 quarter. The position peaked at $0 in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • Kavar Capital Partners Group reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 3 Aegerion Pharmaceuticals shares in Q1 2014.
  • Kavar Capital Partners Group first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Kavar Capital Partners Group's Aegerion Pharmaceuticals position peaked at $0 in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on Kavar Capital Partners Group's 13F filing for Q1 2014, filed 7 Jan 2019.